Business
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
MOUNTAIN VIEW, Calif., May 04, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at the 2026 Annual Meeting of the Society of Biological Psychiatry (SOBP).
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/e36b1a0a7253afdcce00d14027acafef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oAUCsrpHedP58W4TTk_CwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMQ--/https://media.zenfs.com/en/business-wire.com/e36b1a0a7253afdcce00d14027acafef","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_nlZF8cI1E4yzoN3_j5RWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY-/https://media.zenfs.com/en/business-wire.com/e36b1a0a7253afdcce00d14027acafef","width":1200,"height":388}},"lazy":false},{"type":"text","content":"— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7 million patient treatment-resistant depression market —","length":255,"tagName":"p","attribs":{}},{"type":"text","content":"— Phase 2b Ongoing with topline data expected in 2H 2027 —","length":58,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 04, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at the 2026 Annual Meeting of the Society of Biological Psychiatry (SOBP).","length":505,"tagName":"p"},{"type":"text","content":"ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3/D2 agonist with antidepressant activity demonstrated across multiple prior studies, and ondansetron, a 5-HT3 antagonist anti-emetic. The novel, patent-protected combination is designed to enable faster titration to higher pramipexole doses by reducing dose-limiting nausea and vomiting — the key barrier that has historically prevented patients from reaching therapeutically effective doses of pramipexole in clinical practice.","length":494,"tagName":"p"},{"type":"text","content":"Presentation Highlights; Phase 2a Trial Design and Results","length":58,"tagName":"p"...